HPLC, UPLC, GC, LC-MS, GC-MS, ICP-MS, FTIR, UV-Vis, Karl Fischer and dissolution — backed by bespoke method development, validation and transfer per ICH Q2(R2). Where quality starts and OOS investigations end.
Bespoke method development tied to product attributes
Method validation per ICH Q2(R2) — specificity, linearity, accuracy, precision, robustness
Method transfer between sponsor, CDMO and Lunar Labs
Verification of compendial methods (USP / Ph. Eur. / BP)
Dissolution-method development for solid oral dosage forms
Stability-indicating method development with forced-degradation
Identification of unknown peaks and unknown impurities
Cleaning verification methods (swabs, rinsates) and TOC support
Reversed-phase, normal-phase, ion-exchange and HILIC for assay, related substances and content uniformity.
Trace-level impurity quantification, metabolite ID and unknown-peak elucidation.
Residual solvents, volatile profiling and structural ID.
Elemental impurities to ICH Q3D, USP <232>/<233>.
Identity, qualitative comparison and impurity-trace screening.
USP Apparatus 1, 2 and (where in scope) 3/4 with auto-sampling.
Coulometric and volumetric water content for solids and liquids.
Titrimetric assays, pH, conductivity, refractive index, optical rotation.
Methods, documentation and acceptance criteria are designed to align with the standards below. This describes design intent — formal accreditations are listed on the About page.
Method development report with rationale
Method validation protocol and report (ICH Q2)
Method transfer protocol and report
Compendial method verification report
Unknown-peak ID memo with structural proposal
Inspection-ready raw data and audit trail
Send a short scope and we'll come back with a quote and indicative timeline within one working day.